Platelet transfusion refractoriness explained

Platelet transfusion refractoriness is the repeated failure to achieve the desired level of blood platelets in a patient following a platelet transfusion. The cause of refractoriness may be either immune or non-immune. Among immune-related refractoriness, antibodies against HLA antigens are the primary cause. Non-immune causes include splenomegaly (enlargement of the spleen), fever, and sepsis.[1]

Cause

Platelet refractoriness can be due to immune causes or non-immune causes.[2] Non-immune causes account for over 80% of cases of platelet refractoriness, and sepsis is one of the most common non-immune causes.[3] [4] HLA alloimmunization is the commonest immune cause of platelet refractoriness.

Non-immune causes

Patient-related

Platelet component-related

Immune causes

Diagnosis

Platelet transfusion refractoriness can be defined in several different ways. All measures of platelet refractoriness are defined by the timing of the post-transfusion platelet count, usually 1 hour post transfusion or 24 hours post transfusion or both.[8]

Platelet increment (PI)

This is the simplest method, and only requires data on the platelet count before and after the transfusion. The platelet increment is also known as the absolute count increment and count increment.

PI = post-transfusion platelet count - pre-transfusion platelet count

However, it is affected by the number of platelets given in the transfusion (platelet dose) and the patient's blood volume. Larger patients and smaller platelet doses decrease the platelet increment. These factors are adjusted for in the other methods of defining platelet refractoriness.

A 1-hour post-transfusion PI of less than 5 to 10 x 109/l is considered evidence of platelet refractoriness. Due to lack of data on platelet dose this is often the only measure of platelet refractoriness that can be performed in routine clinical practice.

Percentage platelet recovery (PPR)

Requires data on the platelet increment (PI), the patient's total blood volume (TBV) - estimated using the patient's weight multiplied by 0.075, and the number of platelets transfused (platelet dose)[9] [10]

PPR = ((PI x TBV)/PD) x 100

At 1 hour post-transfusion, a PPR < 20% is considered evidence of platelet refractoriness. At 16 hours post-transfusion a PPR < 10% is considered evidence of platelet refractoriness.

Percentage platelet increment (PPI)

PPI is very similar to the percentage platelet recovery (PPR) but there has been an additional adjustment for splenic pooling of platelets (PPR multiplied by 2/3)

PPI = PPR/0.67 = ((PI / 0.67) x TBV)/PD x 100

Corrected count increment (CCI)

This requires data on the platelet increment (PI, in platelets/μL), the patient's Body surface area (BSA, in m2), and the number of platelets transfused (PD, in 1011).

{CCI}=PI*

BSA
PD

For example, a PI of 25,000 platelets/μL, a BSA of 1.8m2 and a PD of 4x1011 gives a CCI of 11,250 platelets*m2/1011μL

At 1 hour post-transfusion a CCI greater than 7500 indicates a sufficient post-transfusion increment, whereas a CCI less than 7500 is considered diagnostic of platelet refractoriness. At 24 hours post transfusion a CCI less than 5000 suggests platelet refractoriness.

Platelet dose

Some blood banks maintain records of the estimated number of platelets in each unit. Current requirements in the US stipulate that a unit of apheresis platelets must contain at least 3.0 x1011 platelets.[11] In England only 1% of adult platelet components are tested to check the number of platelets meet the minimum required standard of 2.4 x 1011 platelets.[12] [13] Only components that contain fewer than 1.6 x 1011 platelets are discarded. This means that there can be a lot of variability in the number of platelets contained within each transfusion.

Treatment

Treatment depends on the underlying cause.[14]

Non-immune causes are usually treated by treating the underlying cause e.g. sepsis.[15]

If there is no obvious non-immune cause, a first step can be to use platelet components that are likely to produce the greatest platelet increment (less than 3 days old and ABO-matched), while further investigations are performed (testing for HLA antibodies).

If an immune cause is suspected and HLA antibodies are detected, then HLA-selected platelet components can be used. Although HLA-selected platelets lead to improved platelet increments at 1 hour post-transfusion,[16] there is currently insufficient evidence to demonstrate their clinical effectiveness at preventing bleeding.

If HLA antibodies are not detected, and HPA antibodies are detected, then HPA-selected or crossmatched platelet components can be used.

HLA and HPA-selected components should not be used if no HLA or HPA antibodies are detected.

Other strategies for managing patients with platelet refractoriness who require procedures include thrombopoietin receptor agonists,[17] complement inhibitors such as eculizumab,[18] and slow infusion.[19]

Notes and References

  1. Stanworth. Simon J.. Navarrete. Cristina. Estcourt. Lise. Marsh. Judith. 2015. Platelet refractoriness – practical approaches and ongoing dilemmas in patient management. British Journal of Haematology. en. 171. 3. 297–305. 10.1111/bjh.13597. 26194869. 9379017. 1365-2141. free.
  2. Web site: Guidelines for the management of platelet transfusion refractoriness. hospital.blood.co.uk. 2018-12-28.
  3. Web site: transfusion.com.au. transfusion.com.au. en. 2018-12-28.
  4. Hod. Eldad. Schwartz. Joseph. 2008. Platelet transfusion refractoriness. British Journal of Haematology. en. 142. 3. 348–360. 10.1111/j.1365-2141.2008.07189.x. 18510692. 1365-2141. 42013955 .
  5. Slichter. Sherrill J.. Granger. Suzanne. Kaufman. Richard M.. Hess. John R.. Ness. P. M.. Strauss. Ronald G.. Assmann. Susan F.. Triulzi. Darrell J.. 2012-06-07. The impact of platelet transfusion characteristics on posttransfusion platelet increments and clinical bleeding in patients with hypoproliferative thrombocytopenia. Blood. en. 119. 23. 5553–5562. 10.1182/blood-2011-11-393165. 1528-0020. 3369689. 22496156.
  6. Book: Chapter 18: Platelet Transfusion, Alloimmunization and Management of Platelet Refractoriness. Petraszko. Tanya. Zeller. Michelle. Canadian Blood Services. 2018.
  7. Estcourt. Lise J. Malouf. Reem. Hopewell. Sally. Trivella. Marialena. Doree. Carolyn. Stanworth. Simon J. Murphy. Michael F. 2017-07-30. Pathogen-reduced platelets for the prevention of bleeding. Cochrane Database of Systematic Reviews. 7. 9 . CD009072. 10.1002/14651858.cd009072.pub3. 1465-1858. 5558872. 28756627.
  8. Rebulla. Paolo. 2005. A mini-review on platelet refractoriness. Haematologica. 90. 2. 247–253. 1592-8721. 15710579.
  9. Pavenski. Katerina. Freedman. John. Semple. J. W.. 2012. HLA alloimmunization against platelet transfusions: pathophysiology, significance, prevention and management. Tissue Antigens. 79. 4. 237–245. 10.1111/j.1399-0039.2012.01852.x. 1399-0039. 22385314.
  10. Rebulla. P.. 1993. Formulae for the definition of refractoriness to platelet transfusion. Transfusion Medicine. en. 3. 1. 91–92. 10.1111/j.1365-3148.1993.tb00108.x. 8038900. 555511. 1365-3148.
  11. Book: AABB. Standards for Blood Banks and Transfusion Services. 2014. AABB. 9781563958878.
  12. Web site: Platelets, Apheresis, Leucocyte Depleted. www.transfusionguidelines.org. 2018-12-29.
  13. Web site: Platelets, Pooled, Buffy Coat Derived, in Additive Solution and Plasma, Leucocyte Depleted. www.transfusionguidelines.org. 2018-12-29.
  14. Cohn CS . Platelet transfusion refractoriness: how do I diagnose and manage? . Hematology Am Soc Hematol Educ Program . 2020 . 1 . 527–532 . December 2020 . 33275694 . 7727584 . 10.1182/hematology.2020000137 .
  15. Nahirniak. Susan. Slichter. Sherrill J.. Tanael. Susano. Rebulla. Paolo. Pavenski. Katerina. Vassallo. Ralph. Fung. Mark. Duquesnoy. Rene. Saw. Chee-Loong. 2015. Guidance on platelet transfusion for patients with hypoproliferative thrombocytopenia. Transfusion Medicine Reviews. 29. 1. 3–13. 10.1016/j.tmrv.2014.11.004. 1532-9496. 25537844.
  16. Pavenski. Katerina. Rebulla. Paolo. Duquesnoy. Rene. Saw. Chee Loong. Slichter. Sherrill J.. Tanael. Susano. Shehata. Nadine. 2013. Efficacy of HLA-matched platelet transfusions for patients with hypoproliferative thrombocytopenia: a systematic review. Transfusion. en. 53. 10. 2230–2242. 10.1111/trf.12175. 23550773. 1839654. 1537-2995.
  17. Satapathy SK, Sundaram V, Shiffman ML, Jamieson BD . Real-world use of avatrombopag in patients with chronic liver disease and thrombocytopenia undergoing a procedure . Medicine (Baltimore) . 102 . 40 . e35208 . October 2023 . 37800793 . 10553023 . 10.1097/MD.0000000000035208 .
  18. Vo P, Purev E, West KA, McDuffee E, Worthy T, Cook L, Hawks G, Wells B, Shalabi R, Flegel WA, Adams SD, Reger R, Aue G, Tian X, Childs R . A pilot trial of complement inhibition using eculizumab to overcome platelet transfusion refractoriness in human leukocyte antigen allo-immunized patients . Br J Haematol . 189 . 3 . 551–558 . May 2020 . 32086819 . 7192788 . 10.1111/bjh.16385 .
  19. Habibi A, Esfandbod M, Ghafari MH, Khashayar P, Najafi A, Moharari RS . Platelet kinetics after slow versus standard transfusions: a pilot study . Ups J Med Sci . 116 . 3 . 212–5 . August 2011 . 21679106 . 3128726 . 10.3109/03009734.2011.569588 .

This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article "Platelet transfusion refractoriness".

Except where otherwise indicated, Everything.Explained.Today is © Copyright 2009-2024, A B Cryer, All Rights Reserved. Cookie policy.